Skip to main content
SpringerLink
Log in

Epidemiology of Prostate Cancer in Europe: Patterns, Trends and Determinants

  • Chapter
  • First Online:
Management of Prostate Cancer

Abstract

Prostate cancer is a substantial public health problem worldwide. It is the most common neoplasm among men and third-ranked cause of cancer death in Europe, with almost 400,000 cases and over 92,000 deaths. Beginning in the early to mid-1990s, the PSA-induced detection of a substantial number of early-stage prostate cancers brought about rapid increases in population-level incidence rates, initially across the higher-income countries of Northern, Western and Southern Europe. Prostate cancer incidence rates are on the increase in populations across all European regions, ranging from 3 to 10 % per annum. At the same time, mortality rates are uniformly in decline in 24 countries in Europe, with the only exception, the Baltic countries, where mortality rates are high and stable or rising.

This chapter seeks to describe the current profile of prostate cancer in Europe, compare recent trends in incidence and mortality and assess the factors that contribute to this evolving landscape. The epidemiology of prostate cancer and the prospects of prevention are reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Al Olama AA. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet. 2014;46(10):1103–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192–202.

    Article  CAS  PubMed  Google Scholar 

  3. Bell KJ, Del Mar C, Wright G, Dickinson J, Glasziou P. Prevalence of incidental prostate cancer: a systematic review of autopsy studies. Int J Cancer. 2015;137:1749–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Bray F, Ferlay J, Laversanne M, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R, Antoni S, Soerjomataram I, Forman D. Cancer incidence in five continents: inclusion criteria, highlights from volume X and the global status of cancer registration. Int J Cancer. 2015;137(9):2060–71.

    Article  CAS  PubMed  Google Scholar 

  5. Brawley OW. Trends in prostate cancer in the United States. J Natl Cancer Inst Monogr. 2012;2012(45):152–6.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Cao Y, Nishihara R, Wu K, Wang M, Ogino S, Willett WC, Spiegelman D, Fuchs CS, Giovannucci EL, Chan AT. Population-wide impact of long-term use of aspirin and the risk for cancer. JAMA Oncol. 2016;2:762–9. doi:10.1001/jamaoncol.2015.6396.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Carstensen B, Read SH, Friis S, Sund R, Keskimäki I, Svensson AM, Ljung R, Wild SH, Kerssens JJ, Harding JL, Magliano DJ, Gudbjörnsdottir S, Diabetes and Cancer Research Consortium. Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals. Diabetologia. 2016;59(5):980–8. [Epub ahead of print].

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Carter BS, Bova GS, Beaty TH, et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol. 1993;150(3):797–802.

    CAS  PubMed  Google Scholar 

  9. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079–92.

    Article  PubMed  Google Scholar 

  10. Chokunonga E, Borok MZ, Chirenje ZM, Nyakabau AM, Parkin DM. Trends in the incidence of cancer in the black population of Harare, Zimbabwe 1991–2010. Int J Cancer. 2013;133(3):721–9.

    Article  CAS  PubMed  Google Scholar 

  11. Cook LS, Goldoft M, Schwartz SM, et al. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol. 1999;161(1):152–5.

    Article  CAS  PubMed  Google Scholar 

  12. Cremers RG, Aben KK, Van Oort IM, Sedelaar JP, Vasen HF, Vermeulen SH, Kiemeney LA. The clinical phenotype of hereditary versus sporadic prostate cancer: HPC definition revisited. Prostate. 2016;76(10):897–904. doi:10.1002/pros.23179. [Epub ahead of print].

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Cremers RG, Galesloot TE, Aben KK, van Oort IM, Vasen HF, Vermeulen SH, Kiemeney LA. Known susceptibility SNPs for sporadic prostate cancer show a similar association with “hereditary” prostate cancer. Prostate. 2015;75(5):474–83.

    Article  CAS  PubMed  Google Scholar 

  14. Doll R, Payne P, Waterhouse J. Cancer incidence in five continents: a technical report. New York: UICC/Springer; 1966.

    Book  Google Scholar 

  15. Duffield-Lillico AJ, Dalkin BL, Reid ME, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int. 2003;91(7):608–12.

    Article  CAS  PubMed  Google Scholar 

  16. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.

    Article  CAS  PubMed  Google Scholar 

  17. Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP. An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015 Nov;33(11):1677-87. doi:10.1007/s00345-015-1514-7. PubMed PMID: 25698456; PubMed Central PMCID:PMC4617845.

    Google Scholar 

  18. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.

    Article  CAS  PubMed  Google Scholar 

  19. Eisinger F, Morère JF, Touboul C, Pivot X, Coscas Y, Blay JY, Lhomel C, Viguier J. Prostate cancer screening: contrasting trends. Cancer Causes Control. 2015 Jun;26(6):949-52. doi: 10.1007/s10552-015-0573-9. PubMed PMID: 25822574.

    Google Scholar 

  20. Gudmundsson J, Sulem P, Gudbjartsson DF, Masson G, Agnarsson BA, Benediktsdottir KR, Sigurdsson A, Magnusson OT, Gudjonsson SA, Magnusdottir DN, Johannsdottir H, Helgadottir HT, Stacey SN, Jonasdottir A, Olafsdottir SB, Thorleifsson G, Jonasson JG, Tryggvadottir L, Navarrete S, Fuertes F, Helfand BT, Hu Q, Csiki IE, Mates IN, Jinga V, Aben KK, van Oort IM, Vermeulen SH, Donovan JL, Hamdy FC, Ng CF, Chiu PK, Lau KM, Ng MC, Gulcher JR, Kong A, Catalona WJ, Mayordomo JI, Einarsson GV, Barkardottir RB, Jonsson E, Mates D, Neal DE, Kiemeney LA, Thorsteinsdottir U, Rafnar T, Stefansson K. A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. Nat Genet. 2012;44(12):1326–9. doi:10.1038/ng.2437. Epub 2012 Oct 28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, et al. Cancer surveillance series: interpreting trends in prostate cancer--part I: evidence of the effects of screening in recent prostate cancer incidence. J Natl Cancer Inst. 1999;91(12):1017–24.

    Article  CAS  PubMed  Google Scholar 

  22. Iwasaki M, Mameri CP, Hamada GS, et al. Secular trends in cancer mortality among Japanese immigrants in the state of Sao Paulo, Brazil, 1979–2001. Eur J Cancer Prev. 2008;17(1):1–8.

    Article  PubMed  Google Scholar 

  23. Jahn JL, Giovannucci EL, Stampfer MJ. The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era. Int J Cancer. 2015;137(12):2795–802. doi:10.1002/ijc.29408. Epub 2015 Jan 8. Review.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Karlsson R, Aly M, Clements M, Zheng L, Adolfsson J, Xu J, Grönberg H, Wiklund F. A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. Eur Urol. 2014;65:169–76.

    Article  CAS  PubMed  Google Scholar 

  25. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335–51.

    Article  CAS  PubMed  Google Scholar 

  26. Kvåle R, Auvinen A, Adami HO, Klint A, Hernes E, Møller B, Pukkala E, Storm HH, Tryggvadottir L, Tretli S, Wahlqvist R, Weiderpass E, Bray F. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst. 2007;99(24):1881–7.

    Article  PubMed  Google Scholar 

  27. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301(1):39–51.

    Article  CAS  PubMed  Google Scholar 

  28. Liu Y, Hu F, Li D, Wang F, Zhu L, Chen W, Ge J, An R, Zhao Y. Does physical activity reduce the risk of prostate cancer? A systematic review and meta-analysis. Eur Urol. 2011;60:1029–44.

    Article  PubMed  Google Scholar 

  29. Lumme S, Tenkanen L, Langseth H, Gislefoss R, Hakama M, Stattin P, Hallmans G, Adlercreutz H, Saikku P, Stenman UH, Tuohimaa P, Luostarinen T, Dillner J. Longitudinal biobanks-based study on the joint effects of infections, nutrition and hormones on risk of prostate cancer. Acta Oncol. 2016;15:1–7. [Epub ahead of print].

    Google Scholar 

  30. Lynch HT, Kosoko-Lasaki O, Leslie SW, Rendell M, Shaw T, Snyder C, D’Amico AV, Buxbaum S, Isaacs WB, Loeb S, Moul JW, Powell I. Screening for familial and hereditary prostate cancer. Int J Cancer. 2016;138:2579–91.

    Article  CAS  PubMed  Google Scholar 

  31. Parkin DM, Bray F, Ferlay J, Jemal A. Cancer in Africa 2012. Cancer Epidemiol Biomarkers Prev. 2014;23(6):953–66. doi:10.1158/1055-9965.EPI-14-0281.

    Article  PubMed  Google Scholar 

  32. Pierce BL. Why are diabetics at reduced risk for prostate cancer? A review of the epidemiologic evidence. Urol Oncol. 2012;30:735–43.

    Article  PubMed  Google Scholar 

  33. Roddam AW, Allen NE, Appleby P, Key TJ, Endogenous Hormones and Prostate Cancer Collaborative Group. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100:170–83.

    Article  CAS  PubMed  Google Scholar 

  34. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, Van der Kwast TH, Van Schaik RH, de Koning HJ, Moss SM,Auvinen A, ERSPC Investigators. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–35.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Sfanos KS, Isaacs WB, De Marzo AM. Infections and inflammation in prostate cancer. Am J Clin Exp Urol. 2013;1(1):3–11.

    PubMed  PubMed Central  Google Scholar 

  36. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215–24.

    Article  CAS  PubMed  Google Scholar 

  37. Wabinga HR, Nambooze S, Amulen PM, Okello C, Mbus L, Parkin DM. Trends in the incidence of cancer in Kampala, Uganda 1991–2010. Int J Cancer. 2014;135(2):432–9. doi:10.1002/ijc.28661. Epub 2014 Feb 27.

    Article  CAS  PubMed  Google Scholar 

  38. WCRF. http://www.wcrf.org/sites/default/files/Prostate-Cancer-2014-Report.pdf. 2014.

  39. Zhang XL, Yan JJ, Pan SH, Pan JG, Ying XR, Zhang GF. Vasectomy and the risk of prostate cancer: a meta-analysis of cohort studies. Int J Clin Exp Med. 2015;8(10):17977–85. eCollection 2015.

    PubMed  PubMed Central  Google Scholar 

  40. Zhou CK, Check DP, Lortet-Tieulent J, Laversanne M, Jemal A, Ferlay J, Bray F, Cook MB, Devesa SS. Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group. Int J Cancer. 2016;138(6):1388–400.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Mathieu Laversanne for development of the tables and figures included in this chapter.

Author information

Authors and Affiliations

  1. Section of Cancer Surveillance, International Agency for Research on Cancer, 150, Cours Albert Thomas, F-69372, Lyon Cedex, Lyon, France

    Freddie Bray

  2. Radboud University Medical Center, Radboud Institute for Health Sciences, Department for Health Evidence & Department of Urology, Nijmegen, The Netherlands

    Lambertus A. Kiemeney

Authors
  1. Freddie Bray
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lambertus A. Kiemeney
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Freddie Bray .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Hôpital Albert Michallon, Grenoble, France

    Michel Bolla

  2. Department of Urology, University Hospitals Leuven, Leuven, Belgium

    Hendrik van Poppel

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Bray, F., Kiemeney, L.A. (2017). Epidemiology of Prostate Cancer in Europe: Patterns, Trends and Determinants. In: Bolla, M., van Poppel, H. (eds) Management of Prostate Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-42769-0_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42769-0_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42768-3

  • Online ISBN: 978-3-319-42769-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation